N/A N=21 Management of Chronic Pain and PTSD in Gulf War Veterans With tDCS+Prolonged Exposure
Chronic Pain · PTSD
Primary: Feasibility of Recruitment as Assessed by Number of Participants Enrolled in the Study — 21 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=34 Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study
Malaria
Primary: Pharmacokinetics Analysis: Half-life, Tmax — 384; 321.6; 2.32; 1.44 hours
N/A N=408 ECG Belt for CRT Response
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume (LVESV) From Baseline to 6 Months Post-implant. — -11.7; -14.7 Percent Change
N/A N=32 Personal Sound Amplification Smartphone Application Feasibility
Hearing Loss
Primary: Sentence Perception in Noise Fine-tuned v Unamplified — 78 percentage of words heard correctly
N/A N=28 NASH Fitness Intervention in Thrombosis Trial (NASHFit)
Liver Diseases · Blood Disorder · Digestive System Disease
Primary: PAI-1 Level — 151.4; 176.2 ng/mL
Early Phase 1 N=8 Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose
Hyperglycaemia (Diabetic)
Primary: Change in HbA1c Levels — 24.3 mmol/mol — p=0.006
Phase 2 N=337 A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
CANCER,NOS
Primary: Number of Participants With Adverse Events (AEs) - Parts 1, 2 and 5 — 4; 16; 15; 284 Participants
N/A N=94 Positive Attitudes Concerning Infant Feeding- a Questionnaire for Women Living With HIV
Human Immunodeficiency Virus
Primary: Knowledge and Experiences of Breastfeeding Among Women Living With HIV — 58; 25; 0; 11 Participants
N/A N=256 Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Breast Cancer · Stage IV Breast Cancer
Primary: 3-year Overall Survival Rate — 67.9; 68.4 percentage of participants — p=0.32
N/A N=3,000 PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement
Stroke
Primary: The Rate of Stroke Through 72 Hours Post TAVR Procedure or Discharge (Whichever Comes First) — 34; 43 Participants
Phase 2 N=52 v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491
Heart Failure With Reduced Ejection Fraction · Dilated Cardiomyopathy
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 2; 5; 3; 0 Participants
Phase 1 N=16 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential
Healthy Volunteers
Primary: Part 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection…
Phase 2 N=221 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
Early Breast Cancer
Primary: Relative Percent Change in Ki67 Scores From Baseline to Week 2 — 25; 33 percent change — p=0.0433
Phase 2 N=740 Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder
Primary: Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B — -9.02; -9.71 score on a scale — p=0.5845
N/A N=40 Virtual Reality and Outpatient Hysteroscopy
Acute Pain · Hysteroscopy
Primary: Worst Pain Scores — 5.65; 7.85 score on a scale